Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Immuno-oncologyOncology
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaOncologyImmuno-oncology
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaImmuno-oncologyOncologyRare Diseases
Patient-reported outcomes support first-line pembrolizumab for NSCLCDecember 6, 2019Lung CancerImmuno-oncologyOncology
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancerDecember 2, 2019OncologyImmuno-oncology
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Multiple MyelomaImmuno-oncologyOncology
Combo elicits lasting responses in metastatic melanomaNovember 25, 2019MelanomaImmuno-oncologyOncologyDermatology
Atezolizumab/bevacizumab may offer benefit to patients with RCCNovember 25, 2019Genitourinary CancerImmuno-oncologyOncology
Combo produces disappointing PFS, promising OS in metastatic colorectal cancerNovember 13, 2019Immuno-oncologyOncology
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinomaNovember 12, 2019Genitourinary CancerImmuno-oncologyOncology
Better overall survival with nivolumab vs. chemo for advanced ESCCNovember 7, 2019Immuno-oncologyOncologyRare Diseases
